Phase IIA Exploratory Study of Oral Milciclib Maleate in Patients With Unresectable or Metastatic Hepatocellular Carcinoma

Trial Profile

Phase IIA Exploratory Study of Oral Milciclib Maleate in Patients With Unresectable or Metastatic Hepatocellular Carcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Milciclib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors Tiziana Life Sciences
  • Most Recent Events

    • 11 Dec 2017 According to a Tiziana Life Sciences media release, independent data monitor committee (IDMC) completed interim analysis from the first six patients, and recommended continuing with the trial.
    • 19 Jul 2017 According to a Tiziana Life Sciences media release, first patient has been enrolled and top line data from this trial is expected in Q4 2018.
    • 07 Jun 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top